Sesamin induces nitric oxide and decreases endothelin-1 production in HUVECs: Possible implications for its antihypertensive effect

Journal of Hypertension

Volumn 22, Issue 12, 2004, Pages 2329-2338

  Lee, Chun Chung ^a   Chen, Pey Rong ^c   Lin, Shankung ^a   Tsai, Shiow Chwen ^a   Wang, Bao Wei ^a   Chen, Wei Wen ^a   Tsai, Chingmin E ^d   Shyu, Kou Gi ^a,b  

^a SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^d CHUNG YUAN CHRISTIAN UNIVERSITY   (Taiwan)

Author keywords

Cyclic GMP; Endothelin converting enzyme; Endothelin 1; Hypertension; Nitric oxide; Nitric oxide synthase; Sesamin

Indexed keywords

ANTIHYPERTENSIVE AGENT; ARGININE; CITRULLINE; CYCLIC GMP; ENDOTHELIN 1; ENDOTHELIN CONVERTING ENZYME; MESSENGER RNA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; SESAMIN;

ARTICLE; BIOASSAY; COLORIMETRY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOTHELIUM CELL; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HYPERTENSION; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; UMBILICAL CORD;

EID: 10244229076     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200412000-00015     Document Type: Article

References (29)

1. Matsumura Y, Kita S, Morimoto S, Akimoto K, Furuya M, Oka N, et al. Antihypertensive effect of sesamin. Protection against deoxycorticosterone acetate-salt-induced hypertension and cardiovascular hypertrophy. Biol Pharm Bull 1995; 18:1016-1019.
2. Matsumura Y, Kita S, Tanida Y, Taguchi Y, Morimoto S, Akimoto K, et al. Antihypertensive effect of sesamin. III. Protection against development and maintenance of hypertension in stroke-prone spontaneously hypertensive rats. Biol Pharm Bull 1998; 21:469-473.
3. Matsumura Y, Kita S, Ohgushi R, Okui T. Effects of sesamin on altered vascular reactivity in aortic rings of deoxycorticosterone acetate-salt-induced hypertensive rat. Biol Pharm Bull 2000; 23:1041-1045.
4. Kita S, Matsumura Y, Morimoto S, Akimoto K, Furuya M, Oka N, et al. Antihypertensive effect of sesamin. II. Protection against two-kidney, one-clip renal hypertension and cardiovascular hypertrophy. Biol Pharm Bull 1995; 18:1283-1285.
5. Noguchi T, Ikeda K, Sasaki Y, Yamamoto J, Seki J, Yamagata K, et al. Effects of vitamin E and sesamin on hypertension and cerebral thrombogenesis in stroke-prone spontaneously hypertensive rats. Hypertens Res 2001; 24:735-742.
6. Nakano D, Itoh C, Takaoka M, Kiso Y, Tanaka T, Matsumura Y. Antihypertensive effect of sesamin. IV. Inhibition of vascular superoxide production by sesamin. Biol Pharm Bull 2002; 25:1247-1249.
7. Nakai M, Harada M, Nakahara K, Akimoto K, Shibata H, Miki W, et al. Novel antioxidative metabolites in rat liver with ingested sesamin. J Agric Food Chem 2003; 51:1666-1670.
8. Shimizu S, Akimoto K, Shinmen Y, Kawashima H, Sugano M, Yamada H. Sesamin is a potent and specific inhibitor of delta 5 desaturase in polyunsaturated fatty acid biosynthesis. Lipids 1991; 26:512-516.
9. Hirose N, Inoue T, Nishihara K, Sugano M, Akimoto K, Shimizu S, et al. Inhibition of cholesterol absorption and synthesis in rats by sesamin. J Lipid Res 1991; 32:629-638.
10. Furchgott RF, Zawadzky JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288:373-376.
11. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327:524-526.
12. Palmer RMJ, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988; 333:664-666.
13. Bredt DS, Hwang PM, Glatt CE, Lowenstein C, Reed RR, Snyder SH. Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase. Nature 1991; 351:714-718.
14. Denninger JW, Marletta MA. Guanylate cyclase and NO/cGMP signaling pathway. Biochim Biophys Acta 1999; 1441:334-350.
15. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332:411-415.
16. Inoue A, Yanagisawa M, Kimura S, Kasuya Y, Miyauchi T, Goto K, et al. The human endothelin family:3 structurally and pharmacologically distinct isopeptides predicted by 3 separate genes. Proc Natl Acad Sci USA 1989; 86:2863-2867.
17. Xu D, Emoto N, Giaid A, Slaughter C, Kaw S, deWit D, et al. ECE-1 a membrane bound metalloprotease that catalyses the proteolytic activation of big endothelin-1. Cell 1994; 78:473-485.
18. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria, J Clin Invest 1973; 52:2745-2756.
19. Lee CC, Shyu KG, Lin S, Wang BW, Liu YC, Chang H. Cell adhesion regulates the plasminogen activator inhibitor-1 gene expression in anchorage-dependent cells. Biochem Biophys Res Comm 2002; 291: 185-190.
20. Maniatis T, Fritsch EF, Sambrook J. Extraction, purification, and analysis of messenger RNA from eukaryotic ceils: Molecular Cloning. A Laboratory Manual. Cold Spring Harbor: Laboratory Press; 1989, pp. 7.1-7.87.
21. Steel RD, Torrie JH. Principles and procedures of statistics. New York: McGraw-Hill; 1960.
22. Hayakawa H, Hirata T, Suzuki E, Kimura K, Kikuchi K, Nagano T, et al. Long-term administration of L-arginine improves nitric oxide release from kidney in deoxycorticosterone acetate-salt hypertensive rats. Hypertension 1994; 23:752-756.
23. Hirata Y, Hayakawa H, Suzuki E, Kimura K, Kikuchi K, Nagano T, et al. Direct measurements of endothelium-derived nitric oxide release by stimulation of endothelin receptors in rat kidney and its alteration in salt-induced hypertension. Circulation 1995; 91:1229-1235.
24. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332:411-415.
25. Goto K, Hama H, Kasuya Y. Molecular pharmacology and pathophysiological significance of endothelin. Jpn J Pharmacol 1996; 72:261-290.
26. Matz RL, Andriantsitohaina R. Age-related endothelial dysfunction potential implications for pharmacotherapy. Drugs Aging 2003; 20:527-550.
27. Barton M, Lattmann T, d'Uscio LV, Luscher TF, Shaw S. Inverse regulation of endothelin-1 and nitric oxide metabolites in tissue with aging implications for the age-dependent increase of cardiorenal disease. J Cardiovasc Pharmacol 2000; 36:S153-156.
28. Goettsch W, Lattmann T, Amann K, Szibor M, Morawietz H, Munter K, et al. Increased expression of endothelin-1 and inducible nitric oxide synthase isoform II in aging arteries in vivo: implications for atherosclerosis. Biochem Biophys Res Commun 2001; 280:908-913.
29. Rossi GP, Seccia TM, Nussdorfer GG. Reciprocal regulation of endothelin-1 and nitric oxide: relevance in the physiology and pathology of the cardiovascular system. Int Rev Cytol 2001; 209:241-272.